Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Rhea-AI Summary

Veracyte, Inc. will present new data at the ASTRO Annual Meeting 2023, highlighting the efficacy of its Decipher Prostate Genomic Classifier. The data includes results from a phase 3 study that evaluated the test's ability to inform treatment decisions for high-risk prostate cancer patients. The company emphasizes that not all prostate cancer molecular tests are equal or interchangeable. The presentations will take place from October 1-4 in San Diego.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.

The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte’s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.

“Data that will be shared at this year’s ASTRO meeting will demonstrate the Decipher Prostate test’s ability to help clinicians make more informed treatment decisions based on the underlying biology of the individual patient’s prostate cancer and will reinforce that prostate cancer molecular tests are not all created equal nor are they interchangeable,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “Our research collaborators will also present data derived from an analysis of the Decipher Genomics Research for Intelligent Discovery (GRID) database, which help advance understanding of the genomic mechanisms that drive treatment response.”

Following are details of the six presentations, which will all take place at the San Diego Convention Center:

Date/Time:			Monday, October 2, 2023, 3:10-3:16 p.m. PT
Title:			Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
Abstract #:			158 (oral presentation)
Presenter:			Ryan Phillips, M.D., Ph.D., The Mayo Clinic
Location:			Room 6 D/E
Date/Time:			Monday, October 2, 2023, 3:20-3:27 p.m. PT
Title:			Cross-Comparison Individual Patient Level Analysis of Three Gene Expression Signatures in Localized Prostate in over 50,000 Men
Abstract #:			159 (oral presentation)
Presenter:			Angela Jia, M.D., Ph.D., Case Western Reserve University
Location:			Room 6 D/E
Date/Time:			Sunday, October 1, 2023, 4:55-5:02 p.m.
Title:			A Precision Medicine Navigator Can Mitigate Inequities Associated with Utilization of Genomic Tests in Black Men with Prostate Cancer
Abstract #:			122 (oral presentation)
Presenter:			Alexander Allen, M.D., University of Maryland Medical Center
Location:			Room 4
Date/Time:			Monday, October 2, 2023, 5:00-6:00 p.m. PT
Title:			Longitudinal Profiling of Tumor RNA Expression Signatures Reveal Key Biological Features Associated with Response to Neoadjuvant Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer
Abstract #:			2539 (poster)
Presenter:			Ariel Marciscano, M.D., Massachusetts General Hospital
Location:			Hall B2
Date/Time:			Tuesday, October 3, 2023, 2:30-3:45 p.m. PT
Title:			Predictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study
Abstract #:			2926 (poster)
Presenter:			John Nikitas, M.D., University of California Los Angeles (UCLA) Radiation Oncology
Location:			Hall B2
Date/Time:			Tuesday, October 3, 2023, 2:30-3:45 p.m. PT
Title:			Dynamic Changes of Molecular Subtype Classification and Genomic Classifier Scores in High-Risk Prostate Cancer Patients Undergoing Pre-Operative Stereotactic Body Radiation Therapy
Abstract #:			2825 (poster)
Presenter:			Marshall Diven, M.D., New York-Presbyterian Brooklyn Methodist Hospital
Location:			Hall B2

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that the Decipher Prostate Genomic Classifier may help clinicians make more-informed treatment decisions based on the underlying biology of the individual patient’s prostate cancer and that the Decipher GRID database data help advance understanding of the genomic mechanism that drives treatment response. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 22, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Decipher Prostate is available in the U.S. as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA. The Decipher GRID database is for Research Use Only. It is not for use to support treatment decisions.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928392023/en/

Investors:

investors@veracyte.com

619-393-1545

Media:

Tracy Morris

VP of Global Corporate Communications

tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.